First Trimester Combined Screening

The First Trimester Combined Screen is a synergistic evaluation that moves beyond maternal age to provide a specific, calculated risk for chromosome anomalies. At the Maternal Fetal Medicine Unit, we utilize the standardized Fetal Medicine Foundation (FMF) protocol to analyze two distinct sets of data:

• Ultrasound Markers: We measure the 'Nuchal Translucency' (NT)—the fluid-filled space at the back of the baby’s neck. In addition to the NT, our subspecialists evaluate 'secondary markers' including the fetal nasal bone, the blood flow through the tricuspid valve, and the ductus venosus. These secondary checks significantly improve accuracy and reduce false positives.
• Maternal Biochemistry: A simple blood test measures two proteins produced by the placenta: Pregnancy-Associated Plasma Protein-A (PAPP-A) and Free Beta Human Chorionic Gonadotropin (free β-hCG).

When these ultrasound and blood parameters are integrated, they reveal underlying biological patterns that may indicate a chromosomal difference. For example, a high β-hCG combined with a low PAPP-A is a known biochemical signature associated with Trisomy 21.

Universal screening is now the international clinical recommendation for all pregnant women. While many patients believe that only 'older' mothers need screening, statistically, the majority of children with chromosomal conditions are born to women under 35, simply because this age group accounts for more births overall.

The Combined Screen is particularly essential for families who:

• Wish to have a comprehensive structural assessment of the baby as early as possible.
• Seek a screening method that evaluates both genetic 'instruction' (via blood markers) and physical 'structure' (via ultrasound).
• Want to avoid the limitations of age-based generic risk tables.

In the UAE, where tertiary fetal medicine is readily available, the Combined Screen acts as the first safety net, detecting not only chromosomal risks but also major physical anomalies like heart defects or abdominal wall issues that cannot be detected by blood-only tests like NIPT.

It is vital to differentiate between a screen and a diagnosis. A screening test gives you a ratio of probability—it does not provide a definitive 'yes' or 'no.'

The Clinical Process: The blood test is ideally performed from 10 weeks onwards, with the ultrasound scan occurring between 11 weeks and 13 weeks + 6 days (specifically when the baby's crown-rump length is between 45mm and 84mm).

Interpreting the Ratio:

• Low Risk (e.g., 1 in 5,000): This means that if 5,000 women had these exact results, only one would have a baby with the condition. This is highly reassuring.
• Intermediate Risk (e.g., 1 in 150 to 1 in 1,000): While still likely indicating a healthy baby, many subspecialists will recommend a secondary screen like NIPT for added precision.
• High Risk (1 in 100 or higher): This is a clinical trigger for a detailed consultation. It indicates a significant enough probability that further investigation is warranted.

A high-risk result is not a diagnosis. If your result falls into the high-risk category, our MFM subspecialists guide you through a structured pathway:

1. Detailed Review: We re-examine the ultrasound markers, biochemistry, dates, and measurements.
2. Advanced Structural Survey: An early anatomy scan may be offered when appropriate.
3. Diagnostic Testing: CVS or amniocentesis can obtain a sample for diagnostic testing. The certainty and scope depend on the laboratory test selected, the condition, sample quality, and interpretation.

Our role is to explain the options and support informed decisions.

The detection rate for Down syndrome using the First Trimester Combined Screen is approximately 90-95% in accredited hands, with a false-positive rate of around 3-5%. This is significantly more effective than the older 'triple test' (60%) or relying on maternal age alone (30%).

Beyond detection, the primary outcome of this screening is informed care. Identifying a condition early allows our team to coordinate with pediatric cardiologists, neonatal intensive care units (NICU), and other specialists well before delivery. This proactive approach ensures that the environment into which the baby is born is optimized for their specific health needs, which is the single most important factor in long-term success.

Referral must happen early. If the baby grows beyond 84mm (the 14-week limit), the nuchal translucency measurement is no longer clinically valid, and the Combined Screen can no longer be performed.

If you have been told your baby has an 'increased NT' or if your blood work shows low PAPP-A, you should be referred to the Maternal Fetal Medicine Unit immediately. We provide one-stop clinics where screening, counseling, and diagnostic testing (like CVS) can often be performed in a single visit, reducing the period of waiting and anxiety for parents. Our unit serves as a tertiary hub for the UAE, managing the most complex screening scenarios with international-grade precision.